ZYGF(SZ:300018)2023-04-21 16:00Financial Performance - The net profit attributable to shareholders of the listed company was 8.8829 million yuan, a decrease of 90.09% year-on-year, primarily due to changes in the fair value of invested funds, which reduced net profit by 8.8534 million yuan [4]. - The company's operating revenue increased by 5.30% compared to the same period last year, indicating that the core business and competitive strengths have not undergone significant adverse changes [4]. - The net profit attributable to shareholders for 2022 was ¥8,882,909.38, a significant decrease of 90.09% from ¥89,609,673.05 in 2021 [26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,319,724.87, up 26.55% from ¥11,315,477.01 in 2021 [26]. - The company's operating revenue for 2022 was ¥442,807,639.89, an increase of 5.30% compared to ¥420,509,087.13 in 2021 [26]. - The basic earnings per share for 2022 were ¥0.02, down 90.09% from ¥0.19 in 2021 [26]. - The diluted earnings per share for 2022 were also ¥0.02, reflecting the same decline of 90.09% from ¥0.19 in 2021 [26]. - The company's operating profit was CNY 30,952,287.98, a decrease of 65.62% year-on-year [55]. - The total profit was CNY 29,799,168.31, a decrease of 67.25% year-on-year [55]. - The company reported a net profit of 72,359,626.83 CNY for 2022, with a distributable profit of 60,454,480.11 CNY [183]. Cash Flow and Investments - The net cash flow from operating activities was ¥39,909,130.70, a slight decrease of 1.99% compared to ¥40,721,419.75 in 2021 [26]. - The net cash increase in cash and cash equivalents was -¥44,543,840.21, a significant improvement of 85.17% compared to -¥300,459,248.82 in the previous year [95]. - Investment cash inflow surged by 486.93% to ¥902,698,147.39, primarily due to the redemption of short-term financial products [95]. - Investment cash outflow increased by 99.22% to ¥987,016,743.56, mainly attributed to the purchase of short-term financial products [95]. - The company reported a significant increase in investment, with total investments rising to CNY 978.52 million, up 104.50% from CNY 478.49 million in the previous year [104]. Revenue Segmentation - The revenue from the power distribution and control segment was ¥352.27 million, accounting for 79.55% of total revenue, with a growth of 2.98% compared to the previous year [68]. - The medical health segment generated ¥90.54 million, which is 20.45% of total revenue, showing a significant increase of 15.41% from ¥78.45 million in 2021 [68]. - The revenue from medical information technology surged by 164.34% to ¥74.56 million, up from ¥28.21 million in 2021 [68]. - The comprehensive energy service business generated revenue of CNY 35,033,110.69, an increase of 18.62% year-on-year [58]. Research and Development - The company has 22 major R&D projects, with 8 new projects added during the reporting period [58]. - The company applied for 5 patents and obtained 14 patents during the reporting period, totaling 60 invention patents and 26 utility model patents by the end of the reporting period [51]. - R&D investment amounted to ¥77,905,022.18 in 2022, representing 17.59% of total revenue, a decrease from 18.99% in 2021 [92]. - The number of R&D personnel decreased by 6.41% to 321 in 2022, with the proportion of R&D personnel in total staff dropping to 40.33% from 42.50% in 2021 [92]. Strategic Initiatives - The company is positioned to benefit from the national push towards smart grid development, with significant investments planned in the energy sector, including over 5,200 billion in 2023 [40]. - The company is focusing on expanding its presence in the healthcare sector, aligning with national policies aimed at enhancing medical infrastructure and technology [41]. - The company is actively participating in the drafting of 57 national, industry, and enterprise standards, with 32 standards already published and implemented by the end of the reporting period [51]. - The company is exploring potential mergers and acquisitions to strengthen its competitive position in the industry [154]. Governance and Compliance - The company has established a governance structure that complies with legal and regulatory requirements, with no significant discrepancies noted [136]. - The company maintained strict information disclosure practices, ensuring timely and accurate communication with stakeholders [135]. - The company emphasizes the importance of compliance with legal and regulatory requirements to maintain effective corporate governance [132]. - The company has committed to ensuring the independence of its management team, including the general manager and financial personnel, who will not hold positions in other companies controlled by the actual controller [197]. Market Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion yuan [154]. - The company aims to enhance its market share for new products while maintaining existing customer relationships and improving sales team effectiveness [124]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025 [167]. - The future outlook for the medical information industry is positive, with expected growth driven by national health policies and the expansion of market space [46].